Study #2017-0696
A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of MGD013, A Bispecific DART Protein Binding PD-1 and LAG-3 In Patients with Unresectable or Metastatic Neoplasms
MD Anderson Study Status
Not Accepting
Treatment Agent
tebotelimab 1 mg, tebotelimab 3 mg, tebotelimab 10 mg, tebotelimab 30 mg, tebotelimab 120 mg, tebotelimab 400 mg, tebotelimab 600 mg, tebotelimab 800 mg, tebotelimab 1200 mg, tebotelimab 300 mg, margetuximab
Description
The primary goal of this Phase 1 study is to characterize the safety and tolerability of tebotelimab and establish the maximum tolerated dose (MTD) of tebotelimab in advanced solid tumors, and tebotelimab in combination with margetuximab in HER2+ advanced solid tumors. Pharmacokinetics (PK), immunogenicity, pharmacodynamics (PD), and the anti-tumor activity of tebotelimab will also be assessed.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Advanced Solid Tumors, Hematologic Neoplasms, Ovarian Cancer, HER2-positive Advanced Solid Tumors, Non Small Cell Lung Cancer, Small-cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Cholangiocarcinoma, Cervical Cancer, TNBC - Triple-Negative Breast Cancer
Study phase:
Phase I
Physician name:
George Blumenschein
Department:
Thoracic/Head & Neck Medical Oncology
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.